- Home
- DUK vs BMY Comparison
DUK vs BMY Comparison
Compare DUK & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$124.40
HOLD
Current Price
$61.20
Company Overview
Basic Information| Metric | DUK | BMY |
|---|---|---|
| Founded | 1904 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3B | 113.5B |
| IPO Year | 2006 | 2006 |
Fundamental Metrics
Financial Performance| Metric | DUK | BMY |
|---|---|---|
| Price | $124.40 | $61.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 28 |
| Target Price | ★ $132.11 | $65.25 |
| AVG Volume (30 Days) | 3.4M | ★ 11.9M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | 3.47% | ★ 4.10% |
| EPS Growth | 10.51 | ★ 178.46 |
| EPS | 1.97 | ★ 2.93 |
| Revenue | $19,624,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $6.14 | $3.54 |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $63.48 | ★ $21.05 |
| Revenue Growth | ★ 35.07 | N/A |
| 52 Week Low | $112.40 | $42.52 |
| 52 Week High | $134.49 | $68.64 |
Technical Indicators
Market Signals| Indicator | DUK | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 50.26 |
| Support Level | $123.94 | $59.91 |
| Resistance Level | $126.19 | $62.77 |
| Average True Range (ATR) | 2.05 | 1.81 |
| MACD | 1.02 | 0.46 |
| Stochastic Oscillator | 87.83 | 68.95 |
Price Performance
Historical Comparison DUK
BMY
About DUK Duke Energy Corporation (Holding Company)
Duke Energy is one of the largest US utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to more than 8 million customers. Its natural gas utilities serve more than 1.6 million customers.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.